Publications by authors named "B Lagana"
Introduction: Psoriatic arthritis (PsA) is a complex condition within the Spondyloarthritis (SpA) group. Recent studies have focused on the important role of the intestinal microbiota in maintaining immunological homeostasis, highlighting how intestinal dysbiosis may act as a trigger for autoimmune diseases. Tofacitinib is a Janus kinase inhibitor (JAK-i) with proven efficacy for the treatment of both rheumatoid arthritis and PsA.
View Article and Find Full Text PDFArticle Synopsis
- Clinical remission is the main goal for managing rheumatoid arthritis (RA), but studies have found that some patients in remission still show signs of synovitis detected by ultrasound.
- The UPARAREMUS study observed the effects of upadacitinib, a selective Janus kinase 1 inhibitor, showing it resulted in significantly higher rates of remission at 24 weeks compared to other treatments like adalimumab and abatacept.
- In this study, 63.6% of patients achieved both clinical and ultrasound remission after 24 weeks, with the likelihood of achieving this higher among bio-naïve patients, indicating that the drug may be more effective in patients who haven't received prior biological treatments.
Article Synopsis
- The study compared the safety and effectiveness of etanercept and adalimumab biosimilars (SB4 and ABP501) with their original versions among patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis in Italy from 2017 to 2020.
- Out of 891 patients, safety profiles were similar; however, biosimilars had higher discontinuation rates due to ineffectiveness, with retention rates at 24 months being 76.5% for biosimilars compared to 81.1% for originators.
- The findings suggest biosimilars are a viable, safe, and more affordable treatment option, offering
Article Synopsis
- Psoriatic arthritis (PsA) is a long-lasting disease that affects people's joints and can cause various other health problems.
- A group of 38 doctors in Italy looked at recent studies to come up with helpful tips on how to manage PsA.
- They created 49 important statements that cover early diagnosis, different types of PsA, related health issues, and goals for treatment.
: We aimed to analyse the incidence and severity of breakthrough infections (BIs) in rheumatoid arthritis (RA) patients after a COronaVIrus Disease 2019 (COVID-19) vaccination booster dose. : We enrolled 194 RA patients and 1002 healthcare workers (HCWs) as controls. Clinical, lifestyle and demographic factors were collected at the time of the third dose, and immunogenicity analyses were carried out in a subgroup of patients at 4-6 weeks after the third dose.
View Article and Find Full Text PDF